- Recommendation ID
- TA575/1
- Question
What are the costs associated with best supportive care?
- Any explanatory notes
(if applicable) The committee noted that the costs of best supportive care are derived from a study published in 2010 and that clinical practice has changed substantially since then. It therefore considered that it would be valuable to have studies investigating:
the costs associated with best supportive care
resource use, including frequency and length of hospitalisation, and associated costs.
Source guidance details
- Comes from guidance
- Tildrakizumab for treating moderate to severe plaque psoriasis
- Number
- TA575
- Date issued
- April 2019
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 17/04/2019 |